Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

The PRECISE-DIET Trial

9. november 2026 oppdatert av: Bettina Ewers, Steno Diabetes Center Copenhagen

Precision Nutrition Versus Standard Dietary Care: Effect of Personalised Nutrition Guidance Based on Continuous Glucose Monitoring in Type 2 Diabetes - The PRECISE-DIET Trial

People with type 2 diabetes receive standard dietary advice to improve glycaemic control. However, blood glucose responses to the same foods can vary considerably between individuals. This randomised controlled trial aims to investigate whether personalised carbohydrate recommendations guided by continuous glucose monitoring (CGM) improve glycaemic control (HbA1c) compared with standard dietary care.

A total of 130 adults with type 2 diabetes will be randomly assigned to one of two groups. The study will include a 6-month intervention period followed by a 6-month follow-up period. The intervention group will receive dietitian-led personalised carbohydrate recommendations informed by CGM data, supplemented by group-based education in carbohydrate counting. The control group will receive standard individual dietary counselling provided by a dietitian without the use of CGM.

The primary outcome is the between-group difference in change in HbA1c from baseline to 6 months.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

130

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Herlev, Danmark, 2730
        • Steno Diabetes Center Copenhagen

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • T2D
  • Diabetes duration of ≥12 months
  • Age ≥18 years
  • HbA1c ≥58 mmol/mol
  • Attending the SDCC outpatient clinic
  • Provided voluntary signed informed consent

Exclusion Criteria:

  • Inability to understand the study information
  • Medical complications that prevent lowering HbA1c to below 58 mmol/mol
  • Use of insulin therapy
  • Low daily carbohydrate intake (defined as below 25 E% or 100 g/day) prior to study inclusion
  • Systematic use of corticosteroids
  • Using or requiring a specialised diet (e.g., protein restriction in kidney disease)
  • Circumstances that affect HbA1c (e.g., liver disease and anaemia)
  • Known or suspected drug or alcohol abuse
  • Pregnancy or breastfeeding or plans of pregnancy within the study period
  • Participation in other clinical trials
  • Individuals with a BMI of <27 kg/m²
  • Initiation of GLP-1 receptor agonist or SGLT inhibitor therapy within the previous 3 months

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Personalised dietary intervention

CGM-supported personalised carbohydrate recommendations

Participants will receive structured, personalised dietary recommendations supported by continuous glucose monitoring (CGM). Initial carbohydrate recommendations will be based on approximately 35% of total energy intake and translated into individual targets expressed as grams of carbohydrate per day and per meal. These targets will be adjusted throughout the intervention based on individual needs and glycaemic responses rather than prescribed as fixed amounts. CGM data will be used to assess individual postprandial glucose responses and guide adjustments to carbohydrate intake and its distribution throughout the day. The intervention will also include education in basic carbohydrate counting and dietitian-led counselling to support the implementation and maintenance of dietary changes.

Aktiv komparator: Standard dietary counselling

Standard dietary counselling for type 2 diabetes

Participants will receive standard dietary counselling for type 2 diabetes based on current dietary recommendations, without CGM-guided personalisation of carbohydrate intake. The counselling will include one initial 60-minute individual consultation with a dietitian, followed by two 30-minute follow-up consultations.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in HbA1c
Tidsramme: Baseline to 6 months

Between-group difference in change in HbA1c (mmol/mol) from baseline to 6 months

Baseline to 6 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in HbA1c at 12 months
Tidsramme: Baseline to 12 weeks and 12 months

Between-group difference in HbA1c change (mmol/mol)

Baseline to 12 weeks and 12 months
Time in range (TIR)
Tidsramme: Baseline, 6 and 12 months

Percentage of CGM time with glucose 3.9-10.0 mmol/L

Baseline, 6 and 12 months
Time above range (TAR)
Tidsramme: Baseline, 6 and 12 months

Percentage of CGM time with glucose >10.0 mmol/L

Baseline, 6 and 12 months
Time below range (TBR)
Tidsramme: Baseline, 6 and 12 months

Percentage of CGM time with glucose <3.9 mmol/L

Baseline, 6 and 12 months
Estimated HbA1c
Tidsramme: Baseline, 6 and 12 months

HbA1c estimated from CGM data (mmol/mol)

Baseline, 6 and 12 months
Change in glycaemic variability
Tidsramme: Baseline, 6 and 12 months

Coefficient of variation (%) derived from CGM

Baseline, 6 and 12 months
Body mass index (BMI)
Tidsramme: Baseline, 6 and 12 months

kg/m²

Baseline, 6 and 12 months
Waist and hip circumference
Tidsramme: Baseline, 6 and 12 months

cm

Baseline, 6 and 12 months
Blood pressure
Tidsramme: Baseline, 6 and 12 months

Systolic and diastolic (mmHg)

Baseline, 6 and 12 months
plasma glucose
Tidsramme: Baseline, 6 and 12 months

mmol/L

Baseline, 6 and 12 months
Plasma insulin
Tidsramme: Baseline, 6 and 12 months

pmol/L

Baseline, 6 and 12 months
C-peptide
Tidsramme: Baseline, 6 and 12 months

pmol/L

Baseline, 6 and 12 months
Total cholesterol
Tidsramme: Baseline, 6 and 12 months

mmol/L

Baseline, 6 and 12 months
LDL cholesterol
Tidsramme: Baseline, 6 and 12 months

mmol/L

Baseline, 6 and 12 months
HDL cholesterol
Tidsramme: Baseline, 6 and 12 months

mmol/L

Baseline, 6 and 12 months
Triglycerides
Tidsramme: Baseline, 6 and 12 months

mmol/L

Baseline, 6 and 12 months
Diabetes distress (questionnaire)
Tidsramme: Baseline, 6 and 12 months

Problem Areas in Diabetes (PAID) score

Baseline, 6 and 12 months
Treatment satisfaction (questionnaire)
Tidsramme: Baseline, 6 and 12 months

Diabetes Treatment Satisfaction Questionnaire (DTSQ) score

Baseline, 6 and 12 months

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in glucose-lowering medication
Tidsramme: Baseline, 6 and 12 months

Changes in type and dose of glucose-lowering medication

Baseline, 6 and 12 months
Personality traits (questionnaire)
Tidsramme: Baseline

Big Five Inventory (BFI-44) scores

Baseline
Dietary intake
Tidsramme: Baseline and 6 months

Total energy intake and macronutrient composition from a 3-day food record

Baseline and 6 months
Physical activity
Tidsramme: Baseline and 6 months

Physical activity level measured with an AX3 accelerometer worn for 7 days

Baseline and 6 months
Carbohydrate estimation ability (questionnaire)
Tidsramme: Baseline, 6 and 12 months

Accuracy of participants' carbohydrate estimates

Baseline, 6 and 12 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. februar 2027

Primær fullføring (Antatt)

1. september 2028

Studiet fullført (Antatt)

1. mars 2029

Datoer for studieregistrering

Først innsendt

9. november 2026

Først innsendt som oppfylte QC-kriteriene

9. november 2026

Først lagt ut (Faktiske)

16. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere